Is Palbociclib Capsule (Ibrance) in shortage?
Palbociclib Capsule is listed by FDA as being discontinued by at least one maker (updated Apr 22, 2026).
Every listed package
FDA tracks shortages per package. What each maker reports, most recently updated first:
- Ibrance, Capsule, 75 mg (NDC 0069-0187-21)
Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet NDC 0069-0284-03 will continue to be manufactured.
Maker contact: 800-533-4535
- Ibrance, Capsule, 100 mg (NDC 0069-0188-21)
Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.
Maker contact: 800-533-4535
Palbociclib Capsule shortage questions
Is Palbociclib Capsule (Ibrance) in shortage?
Palbociclib Capsule is listed by FDA as being discontinued by at least one maker (updated Apr 22, 2026).
What should I do if I can’t get Palbociclib Capsule?
Don’t stop or ration it on your own. Ask your pharmacist whether another strength, package size or maker is in stock, and ask your prescriber about an alternative if none is.
Source: FDA Drug Shortages Database via openFDA. FDA notes that openFDA data is unvalidated and should not be used to make decisions about medical care; ask your pharmacist or prescriber before changing any medication. FDA Drug Shortages Database.